Novartis finds a third-generation scion to an aging Gleevec, successfully taking on a Pfizer rival for last-chance CML patients

John Carroll

Editor & Founder

Nearly 20 years after Novartis’ fading blockbuster Gleevec transformed the treatment of chronic myeloid leukemia and inspired a wave of new treatments to follow, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Novartis finds a third-generation scion to an aging Gleevec, successfully taking on a Pfizer rival for last-chance CML patients

John Carroll

Editor & Founder

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Can Bill Anderson save Bayer?

Updated: Lilly joins Trump administration to announce $27B manufacturing commitment

Verve is latest gene editing company to suffer setback, as Vertex walks away from pact

CDC is investigating five hospitalizations after use of Valneva’s chikungunya vaccine

FDA meeting to pick next winter's flu shot is canceled, in ominous sign for US vaccine policy

How AI can address ongoing challenges in the life sciences industry

No­var­tis finds a third-gen­er­a­tion scion to an ag­ing Gleevec, suc­cess­ful­ly tak­ing on a Pfiz­er ri­val for last-chance CML pa­tients

Editor & Founder

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Novartis finds a third-generation scion to an aging Gleevec, successfully taking on a Pfizer rival for last-chance CML patients